July, 2024
July 2024
Studies conducted by Dana-Farber at this year’s AACR Annual Meeting
May 25, 2024, 14:28

Studies conducted by Dana-Farber at this year’s AACR Annual Meeting

Dana-Farber Cancer Institute shared on LinkedIn:

“Numerous studies conducted by Dana-Farber researchers show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers. The results of these studies, along with dozens of others led by Dana-Farber faculty, were presented at this year’s American Association for Cancer Research (AACR) Annual Meeting last month in California.

Notable research from Dana-Farber researchers included:

Novel ADC and Immunotherapy Combo Shows Promise in Endometrial Cancer Subtype
Rebecca Porter, MD, PhD, a medical oncologist in the Gynecological Oncology Program of the Susan F. Smith Center for Women’s Cancers, presented results of a small, investigator-initiated phase 2 study of a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor.

Blood Test May Identify Patients with Non-Small Cell Lung Cancer Subtype Who Can Benefit from Combination Therapy
Pasi Jänne, MD, PhD, senior vice president for Translational Medicine, presented an update to his practice-changing FLAURA2 clinical trial published last year, revealing that patients with non-small cell lung cancer (NSCLC) marked by a mutation in the EGFR gene fared significantly better when treated with the drug osimertinib plus platinum-based chemotherapy than with osimertinib alone.

Exercise Program Can Improve Heart Function in Cancer Survivors
Cami Christopher, a research scientist in the Department of Medical Oncology, Population Sciences, presented findings suggesting that a moderate to vigorous aerobic and resistance exercise program can improve a key aspect of heart function in survivors of breast, prostate, and colorectal cancer.

Study Provides First Large-Scale Look at Genetic Architecture of Prostate Cancer in Sub-Saharan Africa
Timothy Rebbeck, PhD, the Vincent L. Gregory Professor of Cancer Prevention, led the first large-scale genomic analysis of prostate cancer in sub-Saharan Africa which revealed that the genetic architecture of the disease – its basic underpinnings in abnormalities in DNA – is unique to Africa and varies across the continent.

In addition, the AACR recognized Rebbeck, Christopher D.M. Fletcher, MD, FRCPath, and Gordon J. Freeman, PhD, with 2024 Scientific Achievement Awards during the Annual Meeting.


Source: Dana-Farber Cancer Institute/LinkedIn

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.